Pharma: Page 11
-
Getty Images
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results
The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative reaction to data for its hives drug and Stoke finalized Phase 3 trial plans.
By BioPharma Dive staff • Jan. 8, 2025 -
Mi-Tah / Shutterstock
Sponsored by Esperion TherapeuticsAn evolution in leadership and vision for this pharma company
Esperion CEO Sheldon Koenig reflects on personal challenges and advancing innovative heart therapies.
Jan. 6, 2025 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Getty Images
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got long-awaited data and BioNTech settled with the NIH.
By BioPharma Dive staff • Jan. 2, 2025 -
Getty Images
Ionis gets a milestone approval; Another top FDA official to step down
The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest FDA leader to leave the agency, and two biotechs cut research deals.
By BioPharma Dive staff • Dec. 20, 2024 -
Courtesy of Novo Nordisk
Novo’s next-gen obesity drug misses expectations in closely watched trial
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.
By Jonathan Gardner • Updated Dec. 20, 2024 -
Getty Images
Regeneron says study data support big bet on new blood thinners
The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair of mid-stage trials.
By Jonathan Gardner • Dec. 19, 2024 -
Permission granted by Novartis
Novartis shutters MorphoSys sites, lays off staff
While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.
By Delilah Alvarado • Dec. 19, 2024 -
Kena Betancur via Getty Images
Merck moves into obesity with deal for Hansoh’s GLP-1 pill
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.
By Jonathan Gardner • Dec. 18, 2024 -
Getty Images
Tessera gets sickle cell funding; Corvus shares slide on eczema data
The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara agreed to a reverse merger and J&J had a drug application rejected.
By BioPharma Dive staff • Dec. 18, 2024 -
Getty Images
Pfizer predicts stability, to Wall Street’s relief
The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty caused by COVID [is] mostly resolved,” its CFO said.
By Ned Pagliarulo • Dec. 17, 2024 -
Getty Images
Sanofi, Teva say study results show gut disease drug could be ‘best in class’
Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.
By Ben Fidler • Dec. 17, 2024 -
Getty Images
Novo builds up manufacturing; Pepgen Duchenne trial put on hold
Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine Biosciences, Checkpoint and Galderma won new FDA approvals.
By BioPharma Dive staff • Dec. 16, 2024 -
Getty Images
Merck calls quits on two immunotherapies for cancer
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 testing.
By Jonathan Gardner • Dec. 16, 2024 -
Getty Images
Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO
Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal. Elsewhere, Gilead CEO Daniel O’Day hired Berger away from Sanofi.
By BioPharma Dive staff • Dec. 13, 2024 -
Getty Images
With new data, Lilly sets pace for next wave of breast cancer drugs
While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace fulvestrant.
By Jonathan Gardner • Updated Dec. 11, 2024 -
Getty Images
BenevolentAI restructures; Lilly preps $15B buyback program
The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.
By BioPharma Dive staff • Updated Dec. 17, 2024 -
kirisa99/istockphoto.com
Sponsored by EvaluateWhat’s behind pharma’s growth boost?
Pharma is forecast for a 7.7% growth rate to 2030. What’s driving it? (hint: it’s not just obesity).
Dec. 9, 2024 -
Permission granted by Almac Clinical Services
Sponsored by Almac Clinical ServicesClinical services organizations are critical to the future of pharma in the APAC market
As APAC contract manufacturing grows, pharma companies turn to outsourcing for cost-effective solutions.
Dec. 9, 2024 -
Scott Olson via Getty Images
Lilly adds to obesity drug production push with $3B investment
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana and will help make more injectable drugs like fast-selling Zepbound.
By Jonathan Gardner • Dec. 6, 2024 -
Getty Images
AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B
The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut spending and the U.S. PTO withdrew a controversial proposed patent rule.
By BioPharma Dive staff • Dec. 6, 2024 -
Getty Images
Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.
By BioPharma Dive staff • Dec. 4, 2024 -
Scott Olson via Getty Images
Obesity drugsLilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.
By Jonathan Gardner • Updated Dec. 4, 2024 -
Getty Images
Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date
Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a key PDUFA date and Fate Therapeutics swapped CEOs.
By BioPharma Dive staff • Dec. 2, 2024 -
Getty Images
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat.
By BioPharma Dive staff • Nov. 27, 2024 -
Getty Images
Obesity drugsAmgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.
By Jonathan Gardner • Nov. 26, 2024
Previous
